Fig. 3

Methyltransferase residues mutated in disease. a DNMT3B–DNMT3L (DNMT3B in yellow; DNMT3L in light green) heterodimer with ICF-associated mutated residues in the FF interface shown in white. PDB: 6KDA. b DNMT3B–DNMT3B (both subunits in yellow) homodimer with ICF-associated mutated residue in the RD interface shown in white. PDB: 6KDA. c DNMT3A–DNMT3L (DNMT3A in dark green; DNMT3L in light green) heterodimer with AML-associated mutated residues in the FF interface shown in white. PDB: 6F57. d DNMT3A–DNMT3A (both subunits in dark green) homodimer with AML-associated mutated residues in the RD interface shown in white. PDB: 6F57. e Rat PRMT1–PRMT1 (subunits in teal and light teal) homodimer with rat residues orthologous to human cancer-associated mutations shown in white. PDB: 3Q7E. f Mouse PRMT7 (NTD in dark blue; CTD in light blue) pseudodimer with mouse residues orthologous to human SBIDDS-associated mutated residues shown in white (amino acid numbering is the same for mouse and human). PDB: 4C4A. g METTL3–METTL14 (METTL3 in dark orange; METTL14 in light orange) heterodimer with METTL14 cancer-associated mutated residues shown in white. PDB: 5K7M. h METTL11A–METTL11B (METTL11A in purple; METTL11B in pink) heterodimer with METTL11B cancer-associated mutated residue shown in white. PDB: 2EX4; 6DUB; modeled as described previously [80]. All modeled using Chimera UCSF [96]